Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Cincinnati, Ohio 45267


Purpose:

To determine the effect of Armodafinil (Nuvigil) on fatigue and sleep in sarcoidosis.


Study summary:

The study will be divided into two halves. Patients will receive either drug or placebo in the first half. Patients receiving active drug will be started at one dose and it can be increased at the second visit. Those patients randomized to placebo will also have their dose adjusted by the investigating physician. The physicians will be blinded as to whether the patient is receiving drug or placebo. In the second half of the study, patients will receive the opposite treatment. Patients will have complete detailed questionnaires regarding their fatigue, sleepiness, and overall quality of life. They will have sleep studies done at the start and after each half of the study to determine the effect of therapy on sleepiness.


Criteria:

Inclusion Criteria: - Diagnosis of sarcoidosis using standard criteria 15. - Disease for more than one year - On stable, systemic therapy - Complain of fatigue which has been present for more than six months. - Over 18 years of age - Provide written informed consent. Exclusion Criteria: - Pregnancy - Change in therapy for sarcoidosis in prior three months - History of ventricular arrythmias


NCT ID:

NCT00555347


Primary Contact:

Principal Investigator
Robert P Baughman, MD
University of Cincinnati


Backup Contact:

N/A


Location Contact:

Cincinnati, Ohio 45267
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.